Grifols (NASDAQ:GRFS) Stock Price Up 10.6% – Still a Buy?

Grifols, S.A. (NASDAQ:GRFS) shares shot up 10.6% during trading on Wednesday . The company traded as high as $7.88 and last traded at $8.17. 971,785 shares were traded during trading, an increase of 27% from the average session volume of 765,705 shares. The stock had previously closed at $7.38.

Analyst Ratings Changes

GRFS has been the subject of a number of research analyst reports. Berenberg Bank raised shares of Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th. Morgan Stanley initiated coverage on Grifols in a report on Wednesday, February 12th. They set an “overweight” rating for the company.

Grifols Price Performance

The stock has a market cap of $5.53 billion, a P/E ratio of 6.88 and a beta of 0.40. The business has a 50-day simple moving average of $7.36 and a 200 day simple moving average of $8.09. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Soleus Capital Management L.P. lifted its stake in Grifols by 46.1% in the fourth quarter. Soleus Capital Management L.P. now owns 6,605,425 shares of the biotechnology company’s stock worth $49,144,000 after purchasing an additional 2,083,722 shares during the last quarter. Norges Bank purchased a new position in shares of Grifols in the fourth quarter valued at $14,434,000. Whitebox Advisors LLC increased its holdings in shares of Grifols by 56.2% in the 3rd quarter. Whitebox Advisors LLC now owns 4,221,483 shares of the biotechnology company’s stock worth $37,487,000 after buying an additional 1,519,093 shares during the last quarter. JPMorgan Chase & Co. raised its position in Grifols by 144.0% during the third quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company’s stock valued at $17,782,000 after purchasing an additional 1,181,959 shares during the period. Finally, Anthracite Investment Company Inc. bought a new position in Grifols during the 3rd quarter valued at about $5,457,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.